Journal article
Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal disorders in clinical settings
D Eratne, SM Loi, QX Li, C Stehmann, CB Malpas, A Santillo, S Janelidze, C Cadwallader, N Walia, B Ney, V Lewis, M Senesi, C Fowler, A McGlade, S Varghese, P Ravanfar, W Kelso, S Farrand, M Keem, M Kang Show all
Alzheimer S and Dementia | Published : 2022
DOI: 10.1002/alz.12549
Abstract
Introduction: Many patients with cognitive and neuropsychiatric symptoms face diagnostic delay and misdiagnosis. We investigated whether cerebrospinal fluid (CSF) neurofilament light (NfL) and total-tau (t-tau) could assist in the clinical scenario of differentiating neurodegenerative (ND) from psychiatric disorders (PSY), and rapidly progressive disorders. Methods: Biomarkers were examined in patients from specialist services (ND and PSY) and a national Creutzfeldt-Jakob registry (Creutzfeldt-Jakob disease [CJD] and rapidly progressive dementias/atypically rapid variants of common ND, RapidND). Results: A total of 498 participants were included: 197 ND, 67 PSY, 161 CJD, 48 RapidND, and 20 c..
View full abstractGrants
Awarded by Royal Melbourne Hospital Neuroscience Foundation
Funding Acknowledgements
We are grateful for funding that supported this work: the Trisno Family Research Grant in Old Age Psychiatry; three NorthWestern Mental Health Research Seed Grants; and the CJDSGN Memorial Award in memory of Michael Luscombe, MACH MRFF, and NHMRC (1185180), Royal Melbourne Hospital Neurosciences Foundation. We thank the AIBL study for their assistance and sharing data, and Brett Trounson for all his assistance. Finally, we thank all our patients and participants, and their families. Piero Perucca is supported by the National Health and Medical Research Council (APP1163708), the Epilepsy Foundation, The University of Melbourne, Monash University, and the Weary Dunlop Medical Research Foundation. Henrik Zetterberg is a Wallenberg Scholar. Kaj Blennow is supported by the Swedish Research Council (#2017-00915), the Swedish Alzheimer Foundation (#AF-742881), Hjarnfonden, Sweden (#FO2017-0243), and the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986). Alexander Santillo has for this work received funding by The Greta and Johan Kock, The Fredrik and Ingrid Thuring, and the Henrik and Ellen Sjobring foundations. The ANCJDR is funded by the Australian Government Department of Health. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.